<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38655">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02105922</url>
  </required_header>
  <id_info>
    <org_study_id>H-4-2013-070.2</org_study_id>
    <secondary_id>H-4-2013-070</secondary_id>
    <nct_id>NCT02105922</nct_id>
  </id_info>
  <brief_title>Effect of Strength Training and Protein Ingestion in Old Versus Very-old</brief_title>
  <official_title>Effect of Strength Training and Protein Ingestion in Old Versus Very-old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <authority>Denmark: The Danish National Committee on Biomedical Research Ethics</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      From 3 interventiongroups in the project with ClinicalTrials.gov ID NCT02034760, namely:

      HRTW: Heavy Strength Training x3/week &amp; 20g whey protein twice daily. LITW: Light Intensity
      Training x3-5/week &amp; 20g whey protein twice daily. WHEY: 20g whey protein twice daily.

      resp. 12, 12 and 16 subjects will be recruited and tested after 3 months of intervention.
      Tests will include muscle cross sectional area (MRi), muscle biopsies (fiber types, size,
      cell- and capillary count), functional- and strength measurements, plasma lipids, HbA1c.
      Tests are to be compared with Project ID NCT01997320.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in muscle cross sectional area</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>MRi scans of quadriceps muscle cross sectional area. The statistical evaluation of the primary outcome measure is done by applying a two way ANOVA test comparing groups: 1) Heavy Resistance Training vs. Light Intensity Training vs. Protein Whey. The statistical evaluation will be performed first as an intension-to-treat analysis and subsequently as a per-protocol analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quadriceps muscle isometric strength</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Isometric unilateral quadriceps force and rate of force development measured in the isokinetic dynamometer device (KinCom) during knee extension at the knee angle 70 deg (with 0 degrees being fully extended).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quadriceps muscle isokinetic strength</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unilateral knee extension (concentric) strength measured in the KinCom device at an angular velocity of 60 degrees/sec.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leg extension muscle power</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unilateral leg extension power measured in the Powerrig device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in muscle structure and signalling</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>From muscle biopsies muscle fiber type distribution and size, capillary density, satellite cell count and activity, selected gene-expression targets and protein concentrations will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 30 s chair stand</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of stand-ups from a chair in 30 seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole body composition and bone mineral density</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Body composition (fat mass, lean mass and bone mass) evaluated by whole-body dual energy x-ray absorptiometry (DXA)-scanning.
Bone mineral density at dominant collum femoris and vertebrae L2-L4 evaluated by DXA-scanning.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in blood parameters and anthropometry</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood: HbA1c, plasma lipids. Anthropometry: Weight, abdominal circumference. Blood pressure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in gait speed</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>400 m gait speed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in grip strength</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Isometric hand grip strength.</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaires and interviews</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Short Form 36</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in habitual activity</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluated by 4 days continuous monitoring by a pedometer device (ActivPal).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in daily macronutrient intake</measure>
    <time_frame>Baseline, 1,5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>4-days self-report of food and beverage intake.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Muscle Loss</condition>
  <arm_group>
    <arm_group_label>Heavy Resistance Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Light Intensity Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein Whey</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Heavy Resistance Training</intervention_name>
    <description>Supervised Heavy Resistance Training three times weekly for 3 months.</description>
    <arm_group_label>Heavy Resistance Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Light Intensity Training</intervention_name>
    <description>Home-based Light Intensity Training three-five times weekly for 3 months.</description>
    <arm_group_label>Light Intensity Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Protein Whey</intervention_name>
    <description>Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.</description>
    <arm_group_label>Protein Whey</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, independently living

          -  Age at least 65 years

        Exclusion Criteria:

          -  Subjects dependent on help/nursing etc.

          -  Chronic medical diseases: Diabetes mellitus, clinical knee or hip osteoarthritis,
             other types of arthritis or connective tissue disorders, active cancer, renal
             diseases, severe chronic obstructive pulmonary disease, cardiac arrhythmias or known
             decreased left ventricular ejection fraction, lactose or gluten intolerance, chronic
             inflammatory bowel diseases, non-treated hyper/hypothyroidism, dementia.

          -  Surgical diseases: Bone, muscle, tendon or joint injuries compromising participation
             in exercise regimens.

          -  Implanted magnetic devices incompatible with MRi-scanning.

          -  Weekly alcohol consumption &gt; 21 units (1 unit equals 4g of ethanol) for men and &gt; 14
             for women.

          -  Medicine except acetylsalicylic acid, paracetamol, thyroid function hormones, statins
             in doses above 40mg/day or if combined with subjective myalgia, ACE-inhibitors,
             Angiotensin II blockers, beta-blockers, calciumantagonists, proton-pump inhibitors,
             thiazides, potassium-sparing diuretics and loop diuretics.

          -  &gt;1 hour of exercise weekly, except light activities such as stretching/gymnastics and
             bike-riding/walking as transportation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasmus Bechshøft, Ph.d.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Holm, Assoc. prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kjær, MD, Proff.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Søren Reitelseder, Ph.d.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bispbebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasmus Bechshøft, MD, Ph.d.stu</last_name>
      <phone>+45 35312710</phone>
      <email>r.bechshoeft@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Søren Reitelseder, M.Sc, Ph.d.</last_name>
      <phone>+45 35313164</phone>
      <email>s.reitelseder@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rasmus Bechshøft, Ph.d. stud</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Holm, Assoc. prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Søren Reitelseder, Ph.d.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Kjær, Proff.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>April 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Lars Holm</investigator_full_name>
    <investigator_title>Ph.D. M.S.</investigator_title>
  </responsible_party>
  <keyword>Frailty</keyword>
  <keyword>Ageing</keyword>
  <keyword>Protein supplementation</keyword>
  <keyword>Protein quality</keyword>
  <keyword>Exercise training</keyword>
  <keyword>Sarcopenia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
